Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xbrane Expands Capacity To Target More Biosimilars

Eyeing Further Blockbuster Biologics After Move To Solna Premises

Executive Summary

Sweden’s Xbrane Biopharma is moving to new premises that will expand its development capacity and allow it to target several blockbuster biologics with patents expiring over the next decade.

You may also be interested in...

Xbrane Sets Cash Target Ahead Of Lucentis Ambitions In 2022

Swedish developer Xbrane Biopharma has identified a timeline to turn its cash flows positive, with plans to roll-out biosimilar Lucentis next year.

What’s Next? Five Things To Look Out For In March

In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.

Xbrane To File Ranibizumab Biosimilar In Europe And US Within 12 Months

Sweden’s Xbrane is aiming to file for approval of its Xlucane (ranibizumab) biosimilar to Lucentis in Europe and the US, and license the rights for the product’s sale and marketing of in Latin America, Japan and China, in the next 12 months.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts